Abstract
Laboratory investigations have demonstrated that blockade of HMG-CoA reductase in vitro reduces lymphocyte proliferation in response to mitogens as well as other facets of the immune system, such as natural killer cell cytotoxicity. However, in this randomized and double-blind clinical investigation, treatment with 20-mg lovastatin for 6 months did not significantly alter several enumerative and functional characteristics of circulating immune cells.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Anticholesteremic Agents / pharmacology
-
Anticholesteremic Agents / therapeutic use
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
-
Hypercholesterolemia / drug therapy
-
Hypercholesterolemia / immunology
-
Immune System / drug effects*
-
Lovastatin / pharmacology*
-
Lovastatin / therapeutic use
-
Middle Aged
Substances
-
Anticholesteremic Agents
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Lovastatin